Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

206.2 0.88

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

200.2

Max

206.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

93M

Pardavimai

400K

745M

P/E

Sektoriaus vid.

81.348

27.489

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.37

Pelno marža

12.43

Darbuotojai

10,030

EBITDA

-55M

201M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+11.49% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.37%

3.99%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.2B

19B

Ankstesnė atidarymo kaina

205.32

Ankstesnė uždarymo kaina

206.2

Naujienos nuotaikos

By Acuity

38%

62%

118 / 530 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-19 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

2025-10-19 23:44; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

2025-10-19 23:37; UTC

Rinkos pokalbiai

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

2025-10-19 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

2025-10-19 23:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-19 23:09; UTC

Rinkos pokalbiai

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

2025-10-19 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

2025-10-19 22:30; UTC

Uždarbis

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

2025-10-19 22:18; UTC

Rinkos pokalbiai

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

2025-10-19 21:50; UTC

Rinkos pokalbiai

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

2025-10-19 21:15; UTC

Rinkos pokalbiai

Investors Need to Change Narrative Toward Scales -- Market Talk

2025-10-19 19:34; UTC

Įsigijimai, susijungimai, perėmimai

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

2025-10-19 19:34; UTC

Įsigijimai, susijungimai, perėmimai

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

2025-10-19 19:33; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

2025-10-19 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

2025-10-19 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

2025-10-19 19:31; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

2025-10-19 19:31; UTC

Įsigijimai, susijungimai, perėmimai

Infratil to Acquire Additional 4.92% Stake in Contact Energy

2025-10-19 16:29; UTC

Uždarbis

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

2025-10-19 11:14; UTC

Uždarbis

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

2025-10-19 11:14; UTC

Uždarbis

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

2025-10-19 11:14; UTC

Uždarbis

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

2025-10-18 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-17 23:25; UTC

Įsigijimai, susijungimai, perėmimai

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

2025-10-17 22:15; UTC

Rinkos pokalbiai

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

2025-10-17 21:15; UTC

Rinkos pokalbiai

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

11.49% į viršų

12 mėnesių prognozė

Vidutinis 225.88 EUR  11.49%

Aukščiausias 240 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

5

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

118 / 530 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat